在线协作性眼结核研究计算器对结核性葡萄膜炎的验证
本研究利用COTS-1数据集中的492例临床疑似结核性葡萄膜炎患者,评估在线COTS计算器评分≥4分推荐启动抗结核治疗的准确性。结果显示COTS-5特异性(88.7%)高于临床判断(29.6%),但敏感性(26%)低于临床判断(95.5%);COTS-4平衡了特异性(64.3%)与敏感性(48.8%)。作者认为评分≥4分比临床判断更特异,COTS-5二次咨询可能减少假阳性。
要点
- COTS计算器评分≥4分推荐启动抗结核治疗,其特异性高于临床判断。
- COTS-5特异性88.7%,显著高于临床判断的29.6%。
- 临床判断敏感性95.5%,显著高于COTS-5的26%。
核心结论
- COTS计算器(评分≥4分)在推荐启动抗结核治疗方面比临床判断更具特异性。
- 临床判断作为第一步能高敏感性识别所有潜在真阳性,但COTS-5(高PPV)二次咨询可能减少假阳性。
- 该工具适用于高患病率、低资源环境,能更有选择性地推荐抗结核治疗用于真正的结核性葡萄膜炎病例。
- 需要大型前瞻性研究来探索计算器敏感性的潜在改进。
研究设计与样本
- 本研究为诊断试验或技术评估。
- 数据来自COTS-1研究数据集,该数据集包含回顾性、观察性记录的结核性葡萄膜炎患者,治疗后随访12个月。
- 患者招募自国际眼科中心。
- 在缺乏传统参考标准的情况下,以12个月抗结核治疗反应对患者进行分类(疾病阳性或阴性)。
- 将COTS-1研究中临床医生在抗结核治疗决策阶段的准确性与COTS计算器评分≥4分进行对比。
主要发现
- 共纳入492例参与者(平均[SD]年龄42.3[19.0]岁;男性233例[47.3%])。
- COTS计算器识别出225例(45.7%)具有高或非常高概率启动抗结核治疗(评分=4或5),111例(22.5%)仅为非常高概率(评分=5)。
- COTS-5特异性为88.7%(95%CI,81.4%-93.8%),高于临床判断的29.6%(95%CI,21.4%-38.8%)。
- 临床判断敏感性为95.5%(95%CI,92.9%-97.4%),高于COTS-5的26%(95%CI,21.6%-30.7%)。
- COTS-4和COTS-5平衡了特异性(64.3%;95%CI,54.9%-73.1%)和敏感性(48.8%;95%CI,43.7%-54%)。
关键数值与推荐
- COTS计算器评分≥4分用于推荐启动抗结核治疗。
- COTS-5特异性88.7%(95%CI,81.4%-93.8%),临床判断特异性29.6%(95%CI,21.4%-38.8%)。
- 临床判断敏感性95.5%(95%CI,92.9%-97.4%),COTS-5敏感性26%(95%CI,21.6%-30.7%)。
- COTS-4和COTS-5特异性64.3%(95%CI,54.9%-73.1%),敏感性48.8%(95%CI,43.7%-54%)。
临床怎么用
- 作者认为COTS计算器(评分≥4分)比临床判断更特异,可用于推荐启动抗结核治疗。
- 作者认为临床判断是高敏感性识别潜在真阳性的良好第一步。
- 作者建议COTS-5(高PPV)二次咨询可能减少假阳性。
- 作者认为该工具适用于高患病率、低资源环境,能更有选择性地推荐抗结核治疗用于真正的结核性葡萄膜炎病例。
局限性
- 需要大型前瞻性研究来探索计算器敏感性的潜在改进。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: This was the first study, to the authors' knowledge, to statistically evaluate the predictive accuracy of Collaborative Ocular Tuberculosis Study (COTS) calculator in guiding initiation of antitubercular therapy (ATT) in patients with clinically suspicious tubercular uveitis (TBU) in an international cohort. OBJECTIVE: To evaluate the accuracy of a score of 4 or greater on the online COTS calculator in recommending ATT initiation. DESIGN, SETTING, AND PARTICIPANTS: This study was an evaluation of a diagnostic test or technology. Data input required for the COTS calculator were extracted from the COTS-1 study dataset, which comprised retrospective, observational records of patients with TBU who were monitored for 12 months after treatment. Patients were recruited from international ophthalmic centers. In the absence of a traditional criterion standard, the 12-month treatment response to ATT was used to classify patients as disease positive or negative. The accuracy of clinicians at the ATT decision-making stage in the COTS-1 study was set against COTS calculator scores of 4 or greater. Diagnostic accuracy metrics, including sensitivity, specificity, positive predictive value (PPV), precision, recall, and F1 score, were computed. Data collected from January 2004 to December 2014 were analyzed. EXPOSURES: COTS calculator to guide initiation of ATT in patients with TBU. MAIN OUTCOMES AND MEASURES: Comparison of accuracy between clinician judgment and the COTS calculator, analyzed at varying scores and further stratified by tuberculosis endemicity. RESULTS: Of the 492 participants (mean [SD] age, 42.3 [19.0] years; 233 male [47.3%]), application of the COTS calculator identified 225 (45.7%) with high or very high probability to start ATT (score = 4 or 5) and 111 (22.5%) with very high probability alone (score = 5). COTS-5 exhibited the highest specificity (88.7%; 95% CI, 81.4%-93.8%) compared with clinician judgment (29.6%; 95% CI, 21.4%-38.8%), and clinician judgment led in sensitivity (95.5%; 95% CI, 92.9%-97.4%) compared with COTS-5 (26%; 95% CI, 21.6%-30.7%). COTS-4 and COTS-5 balanced specificity (64.3%; 95% CI, 54.9%-73.1%) and sensitivity (48.8%; 95% CI, 43.7%-54%). PPV and sensitivity were consistently higher in the endemic group for all 3 tests. CONCLUSIONS AND RELEVANCE: Results of this diagnostic study suggest that the COTS calculator (score ≥4) was more specific than clinician judgment for ATT initiation. Although clinician judgment is a good first step to identify all potential true positives (with high sensitivity), a second consultation with COTS-5 (with high PPV) may lead to less false positives. This tool, apt for high-prevalence, low-resource settings, recommends ATT more selectively for genuine TBU cases. Large prospective studies are essential to explore potential improvements in the calculator's sensitivity.
引用
- Zhang L, Rojas-Carabali W, Choo SS, et al. Validation of the Online Collaborative Ocular Tuberculosis Study Calculator for Tubercular Uveitis. JAMA Ophthalmol. 2024. PMID: 39480402. doi:10.1001/jamaophthalmol.2024.4567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。